within Pharmacolibrary.Drugs.ATC.G;

model G01AA03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.3333333333333335e-07,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00395,
    k12             = 0.075,
    k21             = 0.075
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G01AA03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Amphotericin B is a polyene antifungal agent used primarily in the treatment of severe, systemic fungal infections. It is considered a drug of choice for life-threatening mycoses, including cryptococcal meningitis and invasive candidiasis. Despite its effectiveness, it is associated with significant nephrotoxicity and infusion-related reactions. Conventional amphotericin B deoxycholate is still in use, while lipid formulations are also approved to reduce toxicity.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with systemic fungal infections, administered intravenous amphotericin B deoxycholate (non-lipid formulation).</p><h4>References</h4><ol><li><p>Hamill, RJ (2013). Amphotericin B formulations: a comparative review of efficacy and toxicity. <i>Drugs</i> 73(9) 919–934. DOI:<a href=\"https://doi.org/10.1007/s40265-013-0069-4\">10.1007/s40265-013-0069-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23729001/\">https://pubmed.ncbi.nlm.nih.gov/23729001</a></p></li><li><p>Abdollahizad, E, et al., &amp; Rezaee, E (2023). Amphotericin B Pharmacokinetics: Inter-strain Differences in Rats Following Intravenous Administration of the Most Commonly Marketed Formulations of the Drug. <i>Iranian journal of pharmaceutical research : IJPR</i> 22(1) e134772–None. DOI:<a href=\"https://doi.org/10.5812/ijpr-134772\">10.5812/ijpr-134772</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38116555/\">https://pubmed.ncbi.nlm.nih.gov/38116555</a></p></li><li><p>Fisher, JF, et al., &amp; Newman, CA (2011). Candida urinary tract infections--treatment. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 52 Suppl 6 S457–S466. DOI:<a href=\"https://doi.org/10.1093/cid/cir112\">10.1093/cid/cir112</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21498839/\">https://pubmed.ncbi.nlm.nih.gov/21498839</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G01AA03;
